1. Home
  2. VITL vs RLMD Comparison

VITL vs RLMD Comparison

Compare VITL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

N/A

Current Price

$9.42

Market Cap

557.9M

ML Signal

N/A

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

N/A

Current Price

$3.43

Market Cap

461.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VITL
RLMD
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
557.9M
461.9M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
VITL
RLMD
Price
$9.42
$3.43
Analyst Decision
Buy
Strong Buy
Analyst Count
10
4
Target Price
★ $13.22
$10.75
AVG Volume (30 Days)
★ 1.8M
1.3M
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
22.03
★ 45.28
EPS
N/A
★ N/A
Revenue
★ $759,444,000.00
$13,070.00
Revenue This Year
$1.33
N/A
Revenue Next Year
$7.03
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
25.26
★ 154.83
52 Week Low
$7.95
$1.80
52 Week High
$43.80
$8.00

Technical Indicators

Market Signals
Indicator
VITL
RLMD
Relative Strength Index (RSI) 41.21 33.22
Support Level $8.73 $3.22
Resistance Level $13.71 $4.44
Average True Range (ATR) 0.53 0.20
MACD -0.03 -0.03
Stochastic Oscillator 17.69 26.07

Price Performance

Historical Comparison
VITL
RLMD

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: